Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting Conditions
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00652795 |
Recruitment Status :
Completed
First Posted : April 4, 2008
Last Update Posted : April 4, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
To Determine Bioequivalence Under Fasting Conditions | Drug: Doxycycline Monohydrate Drug: Monodox | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 36 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Official Title: | Randomized, 2-Way Crossover, Bioequivalence Study of Doxycycline 150 mg Tablet and Monodox 50 mg Capsule Administered as 1 x 150 mg Tablet or 3 x 50 mg Capsules in Healthy Subjects Under Fasting Conditions |
Study Start Date : | July 2004 |
Actual Primary Completion Date : | September 2004 |
Actual Study Completion Date : | September 2004 |

Arm | Intervention/treatment |
---|---|
Experimental: A
Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.
|
Drug: Doxycycline Monohydrate
Tablets, 150 mg, single-dose
Other Name: Monodox |
Active Comparator: B
Subjects received the Oclassen's product (Monodox) Capsules under fasting conditions.
|
Drug: Monodox
Capsules 50 mg (3 x 50 mg dose), single-dose
Other Name: Doxycycline Monohydrate |
- Rate and extent of absorption [ Time Frame: 24 hours ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male or non-childbearing potential female, smoker or non-smokers
- 18 years of age and older
- Non-childbearing potential female subjects is defined as post-menopausal state: absence of menses for 12 months prior to drug administration or hysterectomy with bilateral oophorectomy, or tubal ligation at least 6 months prior to drug administration
- Capable of consent
Exclusion Criteria:
- Clinically significant illnesses within 4 weeks of the administration of study medication
- Clinically significant surgery within 4 weeks prior to the administration of the study medication
- Any clinically significant abnormality found during medical screening
- Any reason which, in the opinion of the medical subinvestigator, would prevent the subject from participating in the study
- Abnormal laboratory tests judged clinically significant
- Positive testing for hepatitis B, hepatitis C or HIV at screening
- ECG abnormalities or vital sign abnormalities at screening
- BMI greater than or equal to 30.0 kg/m2
- History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than fourteen units of alcohol per week
- History of drug abuse or use of illegal drugs: soft drugs (marijuana) within 3 months prior to the screening visit or hard drugs (cocaine, PCP, crack) within 1 year prior to the screening visit or positive urine drug screen at screening
- History of allergic reactions to heparin, doxycycline, or other related drugs
- Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication
- Use of an investigational drug or participation in an investigational study, within 30 days prior to administration of the study medication.
- Clinically significant history or presence of any clinically significant gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug
- Any clinically significant history or presence of clinically significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or metabolic disease
- Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication, except for topical products without systemic absorption
- Difficulty to swallow study medication
- Smoking more than 25 cigarettes per day Any food allergy, intolerance, restriction or special diet that, in the opinion of the Medical Sub-Investigator, could contraindicate the subject's participation in the study A depot injection or an implant of any drug within 3 months prior to administration of study medication
- Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study)prior to the administration of the study medication (50 mL to 300 mL of whole blood within 30 days, 301 mL to 500 mL of whole blood within 45 days, or more than 500 mL of whole blood within 56 days prior to drug administration)
- History or presence of clinically significant gastro-oesophageal reflux, stomach ulcers, or indigestions
- History or presence of clinically significant severe renal or hepatic dysfunction
- History or presence of clinically significant myasthenia gravis
- Breast-feeding subject
- Positive urine pregnancy screen

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00652795
Canada, Quebec | |
Anapharm | |
Sainte-Foy, Quebec, Canada, G1V 2K8 |
Principal Investigator: | Benoit Girard, M.D. | Anapharm |
Responsible Party: | Alfred Elvin/Director of Biopharmaceutics, Par Pharmaceutical, Inc. |
ClinicalTrials.gov Identifier: | NCT00652795 |
Other Study ID Numbers: |
40074 |
First Posted: | April 4, 2008 Key Record Dates |
Last Update Posted: | April 4, 2008 |
Last Verified: | April 2008 |
bioequivalence doxycycline monohydrate fasting |
Disease Pathologic Processes Doxycycline Anti-Bacterial Agents |
Anti-Infective Agents Antimalarials Antiprotozoal Agents Antiparasitic Agents |